Background: Many studies confirm the safety and efficacy of botulinum toxin type A in a variety of clinical indications. Its use for treatment of hyperfunctional facial lines has become the most popular cosmetic procedure. These case studies comprise an evaluation of the long-term treatment of two subjects treated with botulinum toxin type A (BOTOX(R), Allergan, Irvine, CA, USA) for hyperfunctional, non reducible, facial lines.

Aims: This paper aims to assess the long-term effectiveness of BOTOX treatment for hyperfunctional facial lines in two subjects over 7 years.

Patients/methods: Two subjects (case 1: female aged 53 years; case 2: male age 50 years) presenting with glabelar, forehead, and periorbital facial lines were treated with BOTOX over a 7-year period. Case 1 received a total of 24 treatments at 4-monthly intervals, and case 2 received 21 treatments at 3- to 6-monthly intervals.

Results: Skin quality continued to improve over time, revealing a smoother, enhanced, yet "natural" look. In particular, non reducible forehead lines were effaced suggesting dermal and epidermal remodeling over long-term treatment. There was no evidence of development of any new wrinkles secondary to BOTOX use, and both subjects continue to report high levels of treatment satisfaction. No safety issues were raised.

Conclusions: These case studies demonstrate that non reducible horizontal forehead lines can show long-term reduction with BOTOX treatment and high levels of subject satisfaction.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1473-2165.2008.00399.xDOI Listing

Publication Analysis

Top Keywords

botulinum toxin
12
toxin type
12
case studies
12
facial lines
12
dermal epidermal
8
epidermal remodeling
8
treatment hyperfunctional
8
hyperfunctional facial
8
long-term treatment
8
botox treatment
8

Similar Publications

As the face ages, the skin, fat, muscle, and fascia descend, and the underlying bone, cartilage, and teeth may lose mass. Oculofacial aging is a multifactorial process that is influenced by genetic, environmental, and lifestyle factors. This review summarizes the patterns of oculofacial aging that are observed across populations, including variations in periorbital hollowing, eyelid ptosis, and skin elasticity.

View Article and Find Full Text PDF

Repetitive intramuscular injections of botulinum neurotoxin (BoNT) have become the treatment of choice for a variety of disease entities. But with the onset of BoNT therapy, the natural course of a disease is obscured. Nevertheless, the present study tries to analyze patients' "suspected" course of disease severity under the assumption that no BoNT therapy had been performed and compares that with the "experienced" improvement during BoNT treatment.

View Article and Find Full Text PDF

Botulinum toxin (BoNT), the most potent substance known to humans, likely evolved not to kill but to serve other biological purposes. While its use in cosmetic applications is well known, its medical utility has become increasingly significant due to the intricacies of its structure and function. The toxin's structural complexity enables it to target specific cellular processes with remarkable precision, making it an invaluable tool in both basic and applied biomedical research.

View Article and Find Full Text PDF

Background: Botulinum toxin is an attenuated neurotoxin of Clostridium Botulinum gram positive bacterial, which is used in medication sialorrhea, cervical dystonia, hyperhidrosis and non-surgical cosmetic operation (aesthetic) such as facial wrinkles and reduced the bulky appearance hypertrophied of masseter muscle. This study was designed to revealed the effect of zygomiticus inoculation of botulinum toxin B in zygomatic muscle of rats on zygomatic bone.

Methods: A total of 25 male albino rats (200-260 gm) were injected facial intramuscular by a single dose of 2.

View Article and Find Full Text PDF

The study aimed to identify expert opinions and obtain recommendations on the management of post-stroke hemiplegic shoulder pain (HSP) and treatment with botulinum toxin A (BoNT-A). A multicenter Delphi study was conducted using an online survey designed by a committee of experts with at least 10 years of experience in post-stroke HSP management with BoNT-A in Spain. Forty-seven panelists (specialists with at least 5 years of experience in post-stroke HSP management with BoNT-A) rated their level of agreement in two rounds based on acceptance by ≥66.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!